AOTMiT: Transparency Council on keratitis, transbronchial biopsy and lymphomas, among others

Agenda:

1. Preparation of a position paper on the qualification of the healthcare benefit:
   "Transbronchial biopsy using electromagnetic bronchoscopic navigation".
2. Preparation of a position paper on the evaluation of the drug Calquence (acalabrutinibum)
   under drug program B.12.FM "Treatment of patients with B-cell lymphoma (ICD-10: C82, C83, C85)".
3. Preparation of a position paper on the evaluation of the drug AKANTIOR (polyhexanidum)
   within the framework of the drug program "Treatment of patients with Acanthamoeba keratitis (ICD-10: H19.2)".
4. Preparation of a position paper on the evaluation of the drug Rystiggo (rozanolixizumabum)
   within the framework of drug program B.157 "Treatment of patients with generalized form of myasthenia gravis (ICD-10: G70.0)".
5. Preparation of a position paper on the evaluation of the product Capvaxive
   (pneumococcal vaccine) for the indication: prevention of pneumococcal infections in adults over 65 years of age.
6. Preparation of a position paper on the evaluation of the drugs Opdivo (nivolumabum) and Yervoy (ipilimumabum)
   under drug program B.5 "Treatment of patients with hepatocellular carcinoma (ICD-10: C22.0) or biliary tract cancer (ICD-10: C22.1, C23, C24.0, C24.1, C24.8, C24.9)".
7. Preparation of an opinion on amendments to drug program B.27
   "Treatment of chronic lung infections in recipients with cystic fibrosis (ICD-10: E84)".

Source: AOTMiT